Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 7,098 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 7,098 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total value of $662,456.34. Following the completion of the sale, the chief executive officer owned 163,733 shares of the company’s stock, valued at $15,281,200.89. This trade represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $94.29 on Friday. The business’s 50 day moving average price is $77.33 and its 200 day moving average price is $70.64. The company has a market cap of $4.85 billion, a price-to-earnings ratio of -109.64 and a beta of 0.48. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. Mirum Pharmaceuticals, Inc. has a one year low of $36.88 and a one year high of $96.84.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. During the same period in the prior year, the business earned ($0.30) EPS. The firm’s quarterly revenue was up 47.1% on a year-over-year basis. On average, research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Baird updated Mirum’s valuation after the company reported a beat-and-raise on results, a development that supports upside and follows recent analyst price-target increases. Baird updates Mirum valuation
• Positive Sentiment: Multiple brokerages have raised targets/ratings in recent weeks (Morgan Stanley, HC Wainwright, Stifel, Robert W. Baird and others), reflecting confidence in revenue growth and the company’s lead product (maralixibat). These upgrades help underpin higher consensus price targets. MarketBeat analyst notes
• Neutral Sentiment: Company fundamentals: Mirum is a late-stage biopharma focused on rare cholestatic liver diseases; recent quarter showed strong revenue growth and an EPS beat, but the company remains loss-making on GAAP metrics and carries leverage. This context supports analyst optimism but also ongoing execution risk. Company profile and results
• Neutral Sentiment: Institutional activity shows modest position changes by funds (small buys/sells), not a clear directional institutional shift. Institutional holdings
• Negative Sentiment: Significant insider selling: several senior executives sold shares on Jan. 22 — CEO Christopher Peetz (7,098 shares), COO Peter Radovich (2,382), CFO Eric Bjerkholt (1,421), SVP Jolanda Howe (926) and insider Joanne Quan (multiple recent sales). The block of insider sales (each at ~\$93.33) reduces insider ownership and is likely weighing on sentiment and the stock today. Insider trades alert

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MIRM. Leerink Partners set a $100.00 price target on shares of Mirum Pharmaceuticals in a research note on Wednesday, December 10th. Morgan Stanley increased their price objective on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 target price on shares of Mirum Pharmaceuticals in a research note on Monday, December 8th. Citigroup reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Finally, Stifel Nicolaus increased their price target on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $102.58.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Eventide Asset Management LLC grew its stake in shares of Mirum Pharmaceuticals by 4.4% in the second quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock valued at $134,224,000 after buying an additional 110,485 shares in the last quarter. Geode Capital Management LLC lifted its stake in Mirum Pharmaceuticals by 6.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,029,616 shares of the company’s stock worth $52,405,000 after acquiring an additional 65,951 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Mirum Pharmaceuticals by 566.8% during the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock valued at $57,965,000 after acquiring an additional 672,118 shares during the period. Boone Capital Management LLC grew its position in Mirum Pharmaceuticals by 6.3% in the 2nd quarter. Boone Capital Management LLC now owns 641,448 shares of the company’s stock valued at $32,643,000 after acquiring an additional 38,130 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in Mirum Pharmaceuticals by 709.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock worth $44,889,000 after purchasing an additional 536,674 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.